share_log

Connect Biopharma Lead Candidate Aces Pivotal Atopic Dermatitis Trial In Chinese Patients

Connect Biopharma Lead Candidate Aces Pivotal Atopic Dermatitis Trial In Chinese Patients

康乃德生物主要候选药物ACES关键特应性皮炎中国患者试验
Benzinga Real-time News ·  2022/10/04 11:41
  • Connect Biopharma Holdings Limited (NASDAQ:CNTB) announced topline results for the primary analysis population of the pivotal trial of CBP-201, in patients with moderate-to-severe atopic dermatitis (AD) in China.
  • This trial evaluates the efficacy and safety of CBP-201 as well as the potential for an extended CBP-201 dosing interval during the maintenance phase of treatment.
  • The primary endpoint of IGA of 0 or 1 ("clear" or "almost clear") with at least 2 grades of reduction at Week 16 from baseline was significantly greater for the CBP-201 (300 mg every two weeks) group with 30.3% of patients showing improvement compared to 7.5% for the placebo group.
  • Related: Connect Biopharma's Candidate For Skin Disease-Associated Itch Shows Encouraging Safety Profile.
  • Significant improvement in pruritus with 35.0% of patients experiencing a reduction of 4 or greater on the Peak Pruritus-Numerical Rating Scale (PP-NRS) compared to 9.6% for placebo.
  • CBP-201 was generally well tolerated, with safety results comparable to placebo.
  • Price Action: CNTB shares are down 0.95% at $1.2975 on the last check Tuesday.
  • 康乃德生物控股有限公司美国纳斯达克公司(CBP：CNTB)宣布了中国中重度特应性皮炎(AD)患者中CBP-201关键试验的主要分析人群的TOPLINE结果。
  • 这项试验评估了CBP-201的有效性和安全性，以及在治疗的维持阶段延长CBP-201剂量间隔的可能性。
  • 在第16周，免疫球蛋白A的主要终点为0或1(“清晰”或“几乎清晰”)，较基线至少降低2级，CBP-201组(每两周300毫克)的患者明显更多，30.3%的患者有改善，而安慰剂组为7.5%。
  • 相关： 康乃德生物治疗皮肤病相关瘙痒的候选药物显示出令人鼓舞的安全性.
  • 瘙痒症状显著改善，35.0%的患者在峰值瘙痒-数字评定量表(PP-NRS)上减少了4次或更多，而服用安慰剂的患者只有9.6%。
  • CBP-201总体耐受性良好，安全性结果与安慰剂相当。
  • 价格行动：招商银行股价周二尾盘下跌0.95%，至1.2975美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发